Table 2 Tumor response
| Â | RECIST 1.1 | Â | mRECIST | Â | ||
HAIC 2d | HAIC 1d | pa | HAIC 2d | HAIC 1d | pa | |
CR | 0 | 0 | Â | 7 (5.8%) | 13 (5.2%) | 0.82 |
PR | 51 (42.5%) | 97 (39.1%) | 0.53 | 53 (44.2%) | 90 (36.3%) | 0.15 |
SD | 37 (30.8%) | 81 (32.7%) | 0.73 | 28 (23.3%) | 74 (29.8%) | 0.19 |
PD | 22 (18.3%) | 48 (19.4%) | 0.82 | 22 (18.3%) | 49 (19.8%) | 0.75 |
NA | 10 (8.3%) | 22 (8.9%) | 0.86 | 10 (8.3%) | 22 (8.9%) | 0.86 |
ORR | 51 (42.5%) | 97 (39.1%) | 0.53 | 60 (50.0%) | 103 (41.5%) | 0.13 |
DCR | 88 (73.3%) | 178 (71.8%) | 0.75 | 88 (73.3%) | 178 (71.8%) | 0.75 |
| Â | RECIST 1.1 | Â | mRECIST | Â | ||
PSM cohort | HAIC 2d | HAIC 1d | pa | HAIC 2d | HAIC 1d | pa |
CR | 0 | 0 | Â | 7 (6.2%) | 4 (3.5%) | 0.35 |
PR | 45 (39.8%) | 41 (36.3%) | 0.58 | 47 (41.6%) | 42 (37.2%) | 0.50 |
SD | 37 (32.7%) | 39 (34.5%) | 0.78 | 28 (27.2%) | 34 (30.1%) | 0.64 |
PD | 21 (18.6%) | 21 (18.6%) | 1 | 21 (18.6%) | 21 (18.6%) | 1 |
NA | 10 (8.8%) | 12 (10.6%) | 0.65 | 10 (8.8%) | 12 (10.6%) | 0.65 |
ORR | 45 (39.8%) | 41 (36.3%) | 0.58 | 54 (47.8%) | 46 (40.7%) | 0.28 |
DCR | 82 (72.6%) | 80 (70.8%) | 0.77 | 82 (72.6%) | 80 (70.8%) | 0.77 |